Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2016 | Research

Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients

Authors: Katsuji Tokuhara, Yosuke Ueyama, Kazuyoshi Nakatani, Kazuhiko Yoshioka, Masanori Kon

Published in: World Journal of Surgical Oncology | Issue 1/2016

Abstract

Background

We investigated the efficacy and prognosis of neoadjuvant chemoradiotherapy (NACRT) for Japanese locally advanced rectal carcinoma patients.

Methods

Fifty-seven patients diagnosed with cT3-4 or any cT/cN+ disease using enhanced computed tomography or magnetic resonance imaging from 2002 to 2014 were enrolled. The male/female ratio was 42/15, and the median age was 67 years. Ra/Rb/Rb-P/P was expressed by 6/35/14/2 patients. Histological tumor types were tub1/tub2/por/muc in 22/30/4/1 patients. For NACRT, radiotherapy doses were 40–50.4 Gy chemotherapy consisted of 5′-DFUR, capecitabine, or S1.

Results

All 57 patients received curative surgical treatment. The anal preservation rate was 65.0 %. The ypStage of 0/I/II/IIIa/IIIb was 7/10/25/11/4 cases. The histological antitumor effect (HATE) was ≥grade (G) 2 and G3 in 31 (54.4 %) and 7 (12.3 %) cases, respectively. Postoperative complications occurred in 17 patients and exceeded GIII (Clavien–Dindo classification) in four patients. Recurrence was observed in 19 patients; the primary local recurrence rate was 5.3 %. The 3-year relapse-free survival (RFS) and overall survival (OS) rates were 64.8 and 95.5 %, respectively; the 5-year RFS and OS rates were 60.2 and 61.0 %, respectively. In multivariate analysis, ypN+ was a high-risk factor for distant organ recurrence. As predictive factors regarding the efficacy of NACRT, a neutrophil concentration <70 % and a neutrophil/lymphocyte ratio <3.0 in peripheral blood prior to treatment indicated that NACRT would be significantly more effective.

Conclusions

NACRT was effective in reducing local recurrence but did not suppress distant organ recurrence in Japanese locally advanced rectal carcinoma patients. A further investigation of an extension of the NACRT regimen is required.

National Cancer Center Japan. Projected cancer statistics. Research center for cancer control and information services, cancer information service. 2014. Available: http://ganjoho.jp/en/index.html. (Accessed 20 December 2015).

Klaassen RA, Nieuwenhuijzen GA, Martijn H, Rutten HJ, Hospers GA, Wiggers T. Treatment of locally advanced rectal cancer. Surg Oncol. 2004;13:137–47.CrossRefPubMed

Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.CrossRefPubMed

Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.CrossRefPubMed

Fleming FJ, Påhlman L, Monson JR. Neoadjuvant therapy in rectal cancer. Dis Colon Rectum. 2011;54:901–12. doi:10.1007/DCR.0b013e31820eeb37.CrossRefPubMed

Benson 3rd AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, et al. NCCN clinical practice guidelines in oncology, rectal cancer version 2. 2015. J Natl Compr Canc Netw. 2015;13(6):719–28.PubMed

Inomata M, Akagi T, Nakajima K, Etoh T, Shiraishi N, Tahara K, et al. Prospective feasibility study to evaluate neoadjuvant-synchronous S-1 + RT for locally advanced rectal cancer: a multicenter phase II trial (UMIN ID: 03396). Jpn J Clin Oncol. 2013;43:321–3. doi:10.1093/jjco/hys219.CrossRefPubMed

Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamijo A, Murayama C, et al. Phase I/II study of preoperative concurrent chemoradiotherapy with S-1 for locally advanced, resectable rectal adenocarcinoma. Oncology. 2011;81:306–11. doi:10.1159/000334580.CrossRefPubMed

Sato T, Ozawa H, Hatate K, Onosato W, Naito M, Nakamura T, et al. A phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. Int J Radiat Oncol Biol Phys. 2011;79:677–83. doi:10.1016/j.ijrobp.2009.11.007.CrossRefPubMed

10.

Sugihara K, Ajioka Y, Ishiguro S, Isomoto H, Iwashita A, Iwama T, et al. Japanese classification of colorectal carcinoma, Eighth Edition. Japanese Society for Cancer of the Colon and Rectum. Tokyo: Kanehara Shuppan; 2013.

11.

Berardi R, Maccaroni E, Onofri A, Morgese F, Torniai M, Tiberi M, et al. Locally advanced rectal cancer: the importance of a multidisciplinary approach. World J Gastroenterol. 2014;20:17279–87. doi:10.3748/wjg.v20.i46.17279.CrossRefPubMedPubMedCentral

12.

Marks J, Nassif G, Schoonyoung H, DeNittis A, Zeger E, Mohiuddin M, et al. Sphincter-sparing surgery for adenocarcinoma of the distal 3 cm of the true rectum: results after neoadjuvant therapy and minimally invasive radical surgery or local excision. Surg Endosc. 2013;27:4469–77. doi:10.1007/s00464-013-3092-3.CrossRefPubMed

13.

Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33. doi:10.1200/JCO.2011.40.1836.CrossRefPubMed

14.

Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644–50.CrossRefPubMed

15.

Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513–8. doi:10.1200/JCO.2013.51.7904.CrossRefPubMed

16.

Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32:1554–62. doi:10.1200/JCO.2013.54.3769.CrossRefPubMed

17.

Toiyama Y, Inoue Y, Saigusa S, Kawamura M, Kawamoto A, Okugawa Y, et al. C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Res. 2013;33:5065–74.PubMed

18.

Li CF, He HL, Wang JY, Huang HY, Wu TF, Hsing CH, et al. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy. J Clin Pathol. 2014;67:1056–61. doi:10.1136/jclinpath-2014-202551.CrossRefPubMed

19.

Oh SY, Sohn SH, Yim H, Lee D, Suh KW, Kim YB. ALDH1 is a prognostic factor for patients treated with neoadjuvant chemoradiotherapy and radical resection for stage III rectal cancer. J Surg Oncol. 2015;11:243–7. doi:10.1002/jso.23792.CrossRef

20.

Tut TG, Lim SH, Dissanayake IU, Descallar J, Chua W, Ng W, et al. Upregulated polo-like kinase 1 expression correlates with inferior survival outcomes in rectal cancer. PLoS One. 2015;10, e0129313. doi:10.1371/journal.pone.0129313.CrossRefPubMedPubMedCentral

21.

Tada N, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, et al. Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets. World J Surg Oncol. 2015;13:30. doi:10.1186/s12957-014-0418-0.CrossRefPubMedPubMedCentral

22.

Heo J, Chun M, Noh OK, Oh YT, Suh KW, Park JE, et al. Sustaining blood lymphocyte count during preoperative chemoradiotherapy as a predictive marker for pathologic complete response in locally advanced rectal cancer. Cancer Res Treat. 2015. doi:10.4143/crt.2014.351 [Epub ahead of print].

23.

García-Flórez LJ, Gómez-Álvarez G, Frunza AM, Barneo-Serra L, Martínez-Alonso C, Fresno-Forcelledo MF. Predictive markers of response to neoadjuvant therapy in rectal cancer. J Surg Res. 2015;194:120–6. doi:10.1016/j.jss.2014.10.005.CrossRefPubMed

24.

Flanagan L, Kehoe J, Fay J, Bacon O, Lindner AU, Kay EW, et al. High levels of X-linked inhibitor-of-apoptosis protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer. Radiat Oncol. 2015;10:131. doi:10.1186/s13014-015-0437-1.CrossRefPubMedPubMedCentral

25.

Krauthamer M, Rouvinov K, Ariad S, Man S, Walfish S, Pinsk I, et al. A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncology. 2013;85:27–32. doi:10.1159/000348385.CrossRefPubMed

26.

Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J. 2006;47:693–700.PubMedPubMedCentral

27.

Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, et al. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2015;91:116–23. doi:10.1016/j.ijrobp.2014.09.031.CrossRefPubMedPubMedCentral

28.

Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558–65. doi:10.1200/JCO.2012.42.8771.CrossRefPubMed

29.

Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER, et al. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113:223–9. doi:10.1016/j.radonc.2014.10.006.CrossRefPubMed

30.

Rödel C, Trojan J, Bechstein WO, Woeste G. Neoadjuvant short- or long-term radio(chemo)therapy for rectal cancer: how and who should be treated? Dig Dis. 2012;30 Suppl 2:102–8. doi:10.1159/000342038.CrossRefPubMed

31.

Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, et al. Multidisciplinary rectal cancer management: 2nd European rectal cancer consensus conference (EURECA-CC2). Radiother Oncol. 2009;92:148–63. doi:10.1016/j.radonc.2009.06.027.CrossRefPubMed

32.

van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014;50:1.e1–1.e34. doi:10.1016/j.ejca.2013.06.048.CrossRef

33.

Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et al. Lancet Oncol. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. 2014;15:1245-1253. doi: 10.1016/S1470-2045(14)70377-8.

34.

Xiao J, Chen Z, Li W, Yang Z, Huang Y, Zheng J, et al. Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial. Cancer Chemother Pharmacol. 2015;76:21–7. doi:10.1007/s00280-015-2763-2.CrossRefPubMed

35.

Clinical Trials. Colorectal cancer. Chemotherapy or chemotherapy + radiation for rectal cancer patients undergoing surgery (the PROSPECT Trial-N1048). 2015. Available: http://www.seattlecca.org/clinical-trials/coloncancer-NCT01515787.cfm. (Accessed 20 July 2015).

Title: Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients
Authors: Katsuji Tokuhara
Yosuke Ueyama
Kazuyoshi Nakatani
Kazuhiko Yoshioka
Masanori Kon
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2016
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-016-0898-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

The Diagnosis of Metastatic Axillary Lymph Nodes of Breast Cancer By Diffusion Weighted Imaging: a meta-analysis and systematic review

Right hepatectomy for a detoured left hepatic artery in hilar cholangiocarcinoma—report of a rare but rational resection

Reconstruct the proximal radius with iliac graft and elastic intramedullary nail fixation after tumor resection

Efficacy of limb salvage with primary tumor resection simultaneously for solitary bone metastasis in limbs

Positive detection of exfoliated colon cancer cells on linear stapler cartridges was associated with depth of tumor invasion and preoperative bowel preparation in colon cancer

Knockdown of ribosomal protein S15A induces human glioblastoma cell apoptosis